目的 探讨托伐普坦治疗慢性心力衰竭(chronic heart failure,CHF)患者的疗效及安全性。方法 将60例CHF患者随机分为对照组与观察组,每组30例。对照组给予常规抗心力衰竭治疗,观察组在对照组基础上加用托伐普坦治疗。于治疗前、治疗后7 d检测24 h尿量、血钠、血钾、尿素氮、肌酐、尿酸、B型利钠肽(BNP)、左室射血分数(LVEF)并评价疗效。结果 治疗7 d 后,与治疗前相比,两组患者24 h尿量、血钠明显改善,BNP下降,差异有统计学意义(P<0.05)。与对照组治疗后比较,观察组尿素氮、肌酐明显下降,LVEF明显升高,差异有统计学意义(P<0.05);但尿酸、血钾未见明显变化。观察组总有效率(90.0%)高于对照组(63.3%),差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 托伐普坦可有效改善CHF患者临床症状,纠正低钠血症,改善心肾功能,且不会引起电解质紊乱,不良反应少。
Abstract
Objective To explore the curative effect and safety of tolvaptan on patients of chronic heart failure(CHF).Methods Sixty patients with chronic heart failure were randomly divided into the control group and observation group(30 cases in each group).The control group was given traditional anti-CHF therapy while the observation group was given traditional anti-CHF therapy plus tolvaptan. The changes of 24 h urine volume、blood sodium、blood potassium、blood urea nitrogen、 creatinine、uric acid、B-type natriuretic peptid(BNP)and left ventricular ejection fraction(LVEF)were detected before treatment and 7 days after treatment. The curative effect of tolvaptan was assessed.Results After 7 days of treatment, 24 h urine volume and blood sodium significantly improved,while the level of BNP decreased in the two groups(P<0.05). Compared with the control group,the level of blood urea nitrogen and creatinine decreased and LVEF increased in the observation group(P<0.05). but the level of uric acid and blood potassium did not significantly change. The total effective rate of the observation group(90.0%)was higher than that of the control group(63.3%)(P<0.05).The difference in the incidence of adverse reactions was of no statistical significance between the two groups(P>0.05).Conclusions Tolvaptan can effectively improve the clinical symptom,correct low sodium blood sickness,improve the cardiac and renal function, cause no electrolyte disturbances or fewer adverse reactions in patients with chronic heart failure.
关键词
托伐普坦 /
慢性心力衰竭 /
血钠 /
尿素氮、肌酐 /
B型利钠肽 /
左室射血分数
Key words
tolvaptan /
chronic heart failure /
blood sodium /
blood urea nitrogen、creatinine /
BNP /
LVEF
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 曹俊雄.冻干重组人脑利钠肽联合左西孟旦治疗急性心力衰竭的临床观察[J].中国药房,2016,27(9):1091-1093.
[2] Teruhiko I,Koichiro K,Tomohito O,et al.Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure design and rationale of the AQUA-TLV study[J].Int Heart,2014,55:264-267.
[3] Dunlay S M,Pereira N L,Kushwaha S S.Contemporary strate-gies in the diagnosis and management of heart failure[J].Mayo Clin Proc,2014,89(5):662-676.
[4] Bettari L, Fiuzat M,Shaw L,et al. Hyponatremia and long-term outomes in chronic heart failure-an observational study from the duke databank for cardiovascular diseases[J].Cardiac Fail,2012,18(1):74-81.
[5] Gilotra N A,Russell S D .Arginine vasopressin as a target in the treatment of acute heart failure[J].World J Cardiol,2014,6(12):1252.
[6] Patra S,Kumar B, Harlalka K K,et al.Short term efficacy and safety of low dose tolvaptan in patients with acute decompensatecl heart failure with hy-ponatremia: a prospective observational pilot study from a single center inSouth India [J].Heart Views,2014,15 ( 1 ) : 1-5.
[7] 中华医学会心血管病学会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南 2014[J].中华心血管病杂志,2014,42(2): 98-122.
[8] 刘 斌. 新活素、左西孟旦和托伐普坦联合应用治疗顽固性心力衰竭疗效观察[J]. 国际心血管病杂志,2015,55(6):431-432.
[9] 谢幸洪,齐永乐. 托伐普坦治疗心力衰竭合并低钠血症患者的效果及安全性探析[J]. 河南医学研究,2014,23(10):106-107.
[10] Doehner W,Frenneaux M,Anker S D.Metabolic impairment in heart failure: the myocardial and systemic perspective[J].J Am Coll Cardiol,2014,64(13): 1388-1400.
[11] Verbrugge F H,Steels P,Grieten L,et al.Hyponatremia in acute decompensated heart failure: depletion versus dilution[J].J Am Coll Cardiol,2015,65(5):480-492.
[12] 周桂坤,邹阳春,王明晓,等.慢性充血性心力衰竭合并低钠血症的病理生理学机制及治疗进展[J] .中国医药导刊,2011,13(3):394-396.
[13] Naglerev, Vanmassenhove J, Vanderveer S N,et al. Diagnosis and treatment of hyponatremia:a systematic- review of clinical practice guidelines and consensus statements[J]. BMC Med,2014,12:1.
[14] Theodosios D Filippatos,Moses S Elisaf,et al.Hyponatremia in patients with heart failure[J].World Cardiol,2013,5(9):317-328.
[15] Mcmurray J J,Adamopoulos S ,Anker S D. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collabora tion with the heart[J]. Eur Heart J,2012,33 14 1787-1847.
[16] Inomata T.Tolvaptan ( vasopressin receptor antagonist) [J].Nihon Rinsho, 2011,69( Suppl 9) : 408-411.
[17] Peri A.Clinical review: the use of vaptans in clinical endocri-nology[J].J Clin Endocrinol Metab,2013,98( 4) : 1321-1332.
[18] O’Connell J B,Alemayehu A.Hyponatremia,heart failure,and the role of tolvaptan[J].Postgrad Med,2012,124(2) : 29-39.
[19] Dasta J F,Chiong J R,Christian R,et al.Update on tolvaptan for the treatment of hyponatremia[J].Expert Rev Pharmaco-econ Outcomes Res,2012,12(4):399-410.
[20] Matsuzaki M,Hori M,Izumi T.et al . Efficacy and safety of tolvaptan in heart failure patients with volume over load despite the standard treatment with conventional diuretics:a phase Ⅲ,randomized,double -blind,placebo -controlled study(QUEST study)[J] .Cardiovasc Drugs Ther,2011,25(Suppl 1):S33-S45.
[21] Hori M.Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure [J]. Future Cardiol,2013,9(2):163-176.
[22] Matsuzaki M,Hori M,Izumi T,et al.Efficacy and safety of Tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics:a phase Ⅲ,randomized,double-blind,placebo-controlled study (QUEST study)[J]. Cardiovasc Drugs Ther,2011,25(Suppl 1):33-45.
[23] Matsue Y,Suzuki M,Seya M,et al.Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population[J]. J Cardiol,2013,61(2):169-174.
[24] Kinugawa K,Sato N,Inomata T,et al. Efficacy and safety of Tolvaptan in heart failure patients with volume overload[J]. Circ J,2014,78(4):844-852.
PDF(637 KB)
